Center-Authored Papers

Filters: Author is Stock, Wendy  [Clear All Filters]
2016
Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I-M, Pei D, Iacobucci I, Valentine M, Pounds SB et al..  2016.  High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016690073. Abstract
Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I et al..  2016.  Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.. Nature communications. 7:13331. Abstract
Pettit K, Stock W, Walter RB.  2016.  Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.. Leukemia & lymphoma. 57(7):1527-33. Abstract
2015
Kayser S, Walter RB, Stock W, Schlenk RF.  2015.  Minimal residual disease in acute myeloid leukemia-current status and future perspectives.. Current hematologic malignancy reports. 10(2):132-44. Abstract
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
2014
Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA et al..  2014.  Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.. British journal of haematology. 164(2):223-32. Abstract
Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK et al..  2014.  Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.. British journal of haematology. Abstract
2013
Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA et al..  2013.  Arsenic Trioxide in Front-line Therapy of Acute Promyelocytic Leukemia (C9710): Prognostic Significance of FLT3 Mutations and Complex Karyotype.. Leukemia & lymphoma. Abstract
2012
Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou D-C et al..  2012.  Treatment-influenced associations of PML-RARα mutations, FLT3 mutations and additional chromosome abnormalities in relapse acute promyelocytic leukemia.. Blood. Abstract
Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL et al..  2012.  FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P et al..  2012.  A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia.. Blood. Abstract